A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

NCT01233258 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

BIOLOGICAL: rFVIII (BAY81-8973) on demand
BIOLOGICAL: rFVIII (BAY81-8973) prophylaxis low-dose
BIOLOGICAL: rFVIII (BAY81-8973) prophylaxis high-dose

Sponsor

Bayer